[1] Elsholtz F, Ro S R, Shnayien S,et al. Inter- and intrareader agreement of NI-RADS in the interpretation of surveillance contrast-enhanced CT after treatment of oral cavity and oropharyngeal squamous cell carcinoma. Am J Neuroradiol, 2020,41(5):26-27. [2] Li M, Li MX, Li MD, et al. Comparison of contrast-enhanced ultrasound and contrast-enhanced computed tomography in evaluating the treatment response to transcatheter arterial chemoembolization of hepatocellular carcinoma using modified RECIST. Eur Radiol, 2020,25(8):25-27. [3] Xu H, Wei W, Mu Y, et al. Efficacy and safety of Chinese patent medicine (Jinlong capsule) in the treatment of advanced hepatocellular carcinoma: a meta-analysis. Biosci Rep, 2020,40(1):16-18. [4] 中华人民共和国卫生部.原发性肝癌诊疗规范(2011 年版).临床肿瘤学杂志 2011,16(10):929-946. [5] Zeng Y Y, Guo W H, Zhang Z,et al. A real-world study of camrelizumab in the treatment of hepatocellular carcinoma. J Clin Oncol, 2021, 39(15):16121-16121. [6] Moten A, Lau K N . Racial disparity in the treatment of hepatocellular carcinoma: Have times changed. J Am Coll Surg,2020, 231(4):167-168. [7] 徐学清,李炳超,冯铠莉.增强CT纹理技术对TACE治疗的原发性肝癌患者术后肿瘤短期进展的预测价值.实用肝脏病杂志,2020,23(3):4-6. [8] Cucchetti A, Serenari M, Sposito C, et al. Including mRECIST in the metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant. J Hepatol,2020,73(2):342-348. [9] Long G, Fang T, Su W, et al. The prognostic value of postoperative circulating cell-free DNA in operable hepatocellular carcinoma. Scan J Gastroenterol,2020,55(12):1441-1446. [10] 吴水天. 增强CT扫描在评估原发性肝癌TACE术后疗效中的应用. 中国CT和MRI杂志, 2022, 20(3):3-5. |